Try For Free 7-Day Free Trial
Amgen is a drug development company focused on discovering, developing, manufacturing and delivering human therapeutics. Amgen uses tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and people's lives. Amgen was founded in 1980 and is based in Thousand Oaks, California.
|Overall||4 of 21|
|Sector (Life Science)||4 of 20|
|Type (Add-on Acquisition)||4 of 20|
|State (California)||2 of 9|
|Country (United States)||4 of 16|
|Year (2005)||1 of 1|
|Size (of disclosed)||6 of 20|
San Francisco, California, United States
Tularik is engaged in the discovery and development of a broad range of novel and superior orally available medicines that act through the regulation of gene expression. Tularik's scientific platform is focused on three therapeutic areas: cancer, inflammation and metabolic disease. Tularik currently has five drug candidates in clinical trials. In the cancer area, Tularik is currently conducting a pivotal study of T67 for the treatment of hepatocellular carcinoma and Phase 2 trials with T607 for the treatment of gastric and esophageal cancer. T487, for the treatment of inflammatory diseases, and T131, for the treatment of type 2 diabetes, are in Phase 2 trials to evaluate safety and pharmacokinetic parameters.
Mountain View, California, United States
Avidia is a privately-held biopharmaceutical company discovering and developing a new class of human therapeutic proteins. Avidia is engineering these Avimer(TM) therapeutics against multiple validated and novel targets to address a wide range of disease areas, including inflammation, oncology and neurology.
Nexus Life Science Partners is a private equity firm that targets private and public healthcare companies located within the United States and around the world. The Firm's focus is on the growth segments of the healthcare industry. In particular, Nexus looks for product-driven life sciences companies developing breakthrough therapeutics for clinical needs, positively altering disease course and associated costs. The firm seeks for each private investment a potential for liquidity within 24 months after initial investment, as well as a 2-3 times return on invested capital. Nexus Life Science Partners was formed in 2001, and is based in New York, New York.
|Overall||5 of 22|
|Sector (Life Science)||5 of 18|
|Type (Add-on Acquisition)||3 of 10|
|State (California)||1 of 6|
|Country (United States)||5 of 19|
|Year (2005)||2 of 2|
|Size (of disclosed)||1 of 9|
Baltimore, Maryland, United States
Guilford Pharmaceuticals discovered, developed and marketed pharmaceutical products, targeting the hospital and neurological markets. The company was acquired by MGI Pharma (Nasdaq: MOGN), an oncology and acute care focused biopharmaceutical company
Cambridge Antibody Technology
Gaithersburg, United Kingdom
Cambridge Antibody Technology (CATG) is a leader in the development of human monoclonal antibodies as new treatments for disease, having developed a pipeline of novel human monoclonal antibodies. HUMIRA, an antibody for the treatment of rheumatoid arthritis, developed in collaboration with Abbott, is on the market.